HIV‐1 genetic variability and clinical implications
MM Santoro, CF Perno - International Scholarly Research …, 2013 - Wiley Online Library
Despite advances in antiretroviral therapy that have revolutionized HIV disease
management, effective control of the HIV infection pandemic remains elusive. Beyond the …
management, effective control of the HIV infection pandemic remains elusive. Beyond the …
Managing drug resistance in cancer: lessons from HIV therapy
C Bock, T Lengauer - Nature Reviews Cancer, 2012 - nature.com
Drug resistance is a common cause of treatment failure for HIV infection and cancer. The
high mutation rate of HIV leads to genetic heterogeneity among viral populations and …
high mutation rate of HIV leads to genetic heterogeneity among viral populations and …
FUBAR: a fast, unconstrained bayesian approximation for inferring selection
B Murrell, S Moola, A Mabona, T Weighill… - Molecular biology …, 2013 - academic.oup.com
Abstract Model-based analyses of natural selection often categorize sites into a relatively
small number of site classes. Forcing each site to belong to one of these classes places …
small number of site classes. Forcing each site to belong to one of these classes places …
Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society–USA Panel
HF Günthard, V Calvez, R Paredes… - Clinical Infectious …, 2019 - academic.oup.com
Background Contemporary antiretroviral therapies (ART) and management strategies have
diminished both human immunodeficiency virus (HIV) treatment failure and the acquired …
diminished both human immunodeficiency virus (HIV) treatment failure and the acquired …
[PDF][PDF] European recommendations for the clinical use of HIV drug resistance testing: 2011 update
AM Vandamme, RJ Camacho, F Ceccherini-Silberstein… - Aids Rev, 2011 - academia.edu
Abstract The European HIV Drug Resistance Guidelines Panel, established to make
recommendations to clinicians and virologists, felt that sufficient new information has …
recommendations to clinicians and virologists, felt that sufficient new information has …
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational …
NI Paton, C Kityo, J Thompson, I Nankya, L Bagenda… - The lancet HIV, 2017 - thelancet.com
Background Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to
impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy …
impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy …
Safety, pharmacokinetics and efficacy of dolutegravir in treatment-experienced HIV-1 infected adolescents: forty-eight-week results from IMPAACT P1093
RM Viani, C Alvero, T Fenton, EP Acosta… - The Pediatric …, 2015 - journals.lww.com
Objective: To assess the pharmacokinetics (PK), safety and efficacy of dolutegravir plus
optimized background regimen in HIV-infected treatment-experienced adolescents …
optimized background regimen in HIV-infected treatment-experienced adolescents …
Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals
A Gonzalez-Serna, JE Min, C Woods… - Clinical infectious …, 2014 - academic.oup.com
Background. Low-level viremia (LLV; human immunodeficiency virus [HIV-1] RNA 50–999
copies/mL) occurs frequently in patients receiving antiretroviral therapy (ART), but there are …
copies/mL) occurs frequently in patients receiving antiretroviral therapy (ART), but there are …
Advances in computational approaches in identifying synergistic drug combinations
Z Sheng, Y Sun, Z Yin, K Tang… - Briefings in …, 2018 - academic.oup.com
Accumulated empirical clinical experience, supported by animal or cell line models, has
initiated efforts of predicting synergistic combinatorial drugs with more-than-additive effect …
initiated efforts of predicting synergistic combinatorial drugs with more-than-additive effect …
HIV-1 genotypic drug resistance testing: digging deep, reaching wide?
K Van Laethem, K Theys, AM Vandamme - Current opinion in virology, 2015 - Elsevier
Highlights•Technological innovations enable the global roll-out of drug resistance
surveillance.•Next-generation sequencing provides an answer for simultaneous resistance …
surveillance.•Next-generation sequencing provides an answer for simultaneous resistance …